Aptamer Group (is a world-leading provider of Optimer™ reagents for use in research, diagnostics and therapeutics. The Company strives to deliver transformational solutions, that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology.
Optimers are next-generation aptamer molecules derived from nucleic acids that function as an antibody alternative. Despite many well-recognised problems with antibodies, the global antibody market is currently worth over $130Bn. Optimers are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
At Aptamer Group, we have successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through our unique technology and processes, we enable scientists and collaborators to make faster, more informed decisions that support discovery and development across the Life Scien
